Vitrolife — M&A Activity 2008

Jul 4, 2008

Press release July 4, 2008 Kungsbacka, Sweden

________________________________________________________________________________________

_________________________________________________________________________________________

Vitrolife acquires further shares in A.T.S.

Vitrolife is acquiring a further 9 percent of the shares in A.T.S. Srl, the distributor of Vitrolife's products in Italy. Vitrolife thereby owns 60 percent of the company, with an option to acquire a further 10 percent within six months. "We are very pleased with how A.T.S has developed over the past six months: the development of both sales and earnings has been stronger than planned" says Magnus Nilsson, Vitrolife's CEO.

In January 2008 Vitrolife acquired 51 percent of the shares in A.T.S. Srl, the distributor of Vitrolife's products in Italy since 1999. The acquisition is in line with Vitrolife's strategy to operate under its own management in key markets and increases the opportunities for A.T.S. to be more aggressive and be able to increase its market share in the Italian market.

In the agreement there is an option for Vitrolife to acquire a further 9 percent of the shares within 6 months and subsequently a further 10 percent within 12 months of the original acquisition date, that is a total of 70 percent. It is the first part of this option that has now been utilized. For the first quarter of 2008, the acquisition positively affected the consolidated sales figure by SEK 2.4 million, with good profitability.

The seller of the shares is Paolo Trabucchi, one of the founders and previously the sole owner of A.T.S.

Approximately 24,000 infertility treatments are performed in Italy per year and the number of fertility centers amounts to approximately 300. The potential market value for instruments and media amounts to SEK 40-50 million.

July 4, 2008 Kungsbacka, Sweden

Magnus Nilsson CEO

Queries should be addressed to: Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61. Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 140 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.

Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.